TW283642B - - Google Patents

Info

Publication number
TW283642B
TW283642B TW083108691A TW83108691A TW283642B TW 283642 B TW283642 B TW 283642B TW 083108691 A TW083108691 A TW 083108691A TW 83108691 A TW83108691 A TW 83108691A TW 283642 B TW283642 B TW 283642B
Authority
TW
Taiwan
Prior art keywords
pyrrolidineacetamide
anxiety
oxo
medicament
alpha
Prior art date
Application number
TW083108691A
Other languages
English (en)
Chinese (zh)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Application granted granted Critical
Publication of TW283642B publication Critical patent/TW283642B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
TW083108691A 1993-09-24 1994-09-21 TW283642B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (1)

Publication Number Publication Date
TW283642B true TW283642B (enExample) 1996-08-21

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083108691A TW283642B (enExample) 1993-09-24 1994-09-21

Country Status (17)

Country Link
US (1) US5447952A (enExample)
EP (1) EP0645139B1 (enExample)
JP (1) JP3688735B2 (enExample)
KR (1) KR950007848A (enExample)
AT (1) ATE191849T1 (enExample)
AU (1) AU672334B2 (enExample)
CA (1) CA2132509A1 (enExample)
DE (1) DE69424009T2 (enExample)
ES (1) ES2145818T3 (enExample)
GB (1) GB9319732D0 (enExample)
HU (1) HU217124B (enExample)
NO (1) NO943521L (enExample)
NZ (1) NZ264506A (enExample)
RU (1) RU2142274C1 (enExample)
SG (1) SG86284A1 (enExample)
TW (1) TW283642B (enExample)
ZA (1) ZA947444B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
YU37602A (sh) 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ATE413875T1 (de) * 2006-01-24 2008-11-15 Teva Pharma Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
AU2007226203A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
PL2164847T3 (pl) * 2007-07-03 2012-02-29 Actelion Pharmaceuticals Ltd Związki 3-azabicyklo[3.3.0]oktanowe
BRPI0814593A2 (pt) * 2007-07-27 2015-01-20 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica que o contém e uso do composto.
CN107243007A (zh) 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
HK1218623A1 (zh) 2013-03-15 2017-03-03 艾吉因生物股份有限公司 用於改善認知功能的方法和組合物
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3890833B1 (en) * 2018-12-04 2023-06-07 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1414845A1 (ru) * 1984-03-23 1988-08-07 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе 1-Тиокарбамоилметилпирролидин-2-тион,обладающий ноотропной активностью, и способ его получени
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
SU1320707A1 (ru) * 1985-01-24 1987-06-30 Ивано-Франковский Институт Нефти И Газа Способ определени износостойкости материалов ма тниковым склерометром
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en) * 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
CA2048003A1 (en) * 1990-08-21 1992-02-22 Serge Burner Tricyclic pyridone derivatives

Also Published As

Publication number Publication date
NO943521D0 (no) 1994-09-22
KR950007848A (ko) 1995-04-15
AU7416994A (en) 1995-04-06
AU672334B2 (en) 1996-09-26
JPH07149639A (ja) 1995-06-13
EP0645139B1 (fr) 2000-04-19
NO943521L (no) 1995-03-27
RU2142274C1 (ru) 1999-12-10
ZA947444B (en) 1995-05-11
NZ264506A (en) 1997-09-22
ES2145818T3 (es) 2000-07-16
HU217124B (hu) 1999-11-29
SG86284A1 (en) 2002-02-19
ATE191849T1 (de) 2000-05-15
EP0645139A1 (fr) 1995-03-29
CA2132509A1 (en) 1995-03-25
JP3688735B2 (ja) 2005-08-31
DE69424009D1 (de) 2000-05-25
DE69424009T2 (de) 2000-09-14
GB9319732D0 (en) 1993-11-10
HUT68299A (en) 1995-06-28
US5447952A (en) 1995-09-05

Similar Documents

Publication Publication Date Title
TW283642B (enExample)
TW249226B (enExample)
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
ZA925128B (en) Pyrrolidine derivatives,their preparation and medicaments containing them
DK0559413T3 (enExample)
IL101819A0 (en) Amidinophenylalanine derivatives,a process for the preparation thereof,use thereof and agents containing these as anticoagulants
FR2658413B1 (fr) Dispositif d'osteosynthese pour la correction des deviations rachidiennes.
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
GR3005470T3 (enExample)
AU3636493A (en) Compounds used in contrast products for radiography
DK0623620T3 (da) 5-HT3-pyrrolopyrazinderivater
AU7593091A (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
EP0469782A3 (en) Treatment of cataract with prostacyclin compounds
EP0377127A3 (de) Verwendung von Myricetin-3-0-beta-D-glucuronid als Arzneimittel
NO920984L (no) Fremgangsmaate for diastereoselektiv reduktiv pinakol-kobling av homokirale alfa-aminoaldehyder
TW232011B (enExample)
CY2065B1 (en) Use of naphthoxazines
GR3015592T3 (en) Pharmaceuticals containing substituted cyclohex-2-en-1-yl-amine derivatives and their use in combatting diseases.
GR3003065T3 (en) Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility
ZA937179B (en) Tetrahydorindazolone pharmaceutical compositions
GR920300126T1 (enExample)
ES2103166A1 (es) Procedimiento para la obtencion de amidinohidrazonas biciclicas.